Analysts have differing opinions on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for BBLG is 0.09M, and currently, short sellers hold a 16.21% ratio of that floaft. The average trading volume of BBLG on June 11, 2025 was 23.53K shares.
BBLG) stock’s latest price update
Bone Biologics Corp (NASDAQ: BBLG)’s stock price has gone rise by 22.88 in comparison to its previous close of 4.52, however, the company has experienced a 15.79% increase in its stock price over the last five trading days. businesswire.com reported 2025-06-06 that BURLINGTON, Mass.–(BUSINESS WIRE)–Bone Biologics Corporation (“Bone Biologics” or the “Company”) (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, today announced a planned reverse stock split of its shares of common stock at a ratio of 1-for-6. The reverse stock split will take effect as of 12:01 a.m. ET, on Tuesday, June 10, 2025, and shares of Bone Biologics are expected to trade on a post-split basis on Nasdaq under the existing trading symbol, “BBLG,”.
BBLG’s Market Performance
BBLG’s stock has risen by 15.79% in the past week, with a monthly rise of 23.61% and a quarterly rise of 10.98%. The volatility ratio for the week is 12.06% while the volatility levels for the last 30 days are 7.15% for Bone Biologics Corp The simple moving average for the past 20 days is 13.69% for BBLG’s stock, with a -18.14% simple moving average for the past 200 days.
BBLG Trading at 22.72% from the 50-Day Moving Average
After a stumble in the market that brought BBLG to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -78.20% of loss for the given period.
#####
#####
Stock Fundamentals for BBLG
The total capital return value is set at -1.5. Equity return is now at value -129.48, with -121.79 for asset returns.
Currently, EBITDA for the company is -4.11 million with net debt to EBITDA at 0.52. The liquidity ratio also appears to be rather interesting for investors as it stands at 12.59.
Conclusion
In a nutshell, Bone Biologics Corp (BBLG) has experienced a mixed performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
